Drug intelligence / Profile preview

IVX-055

Development stage: Preclinical
Lead developer: ImmVirx
Modality: Oncolytic Viruses → Oncolytic Therapeutics, RNA Therapeutics → Nucleic Acid Therapeutics
Administration: Intratumoral, Intravenous

Overview

IVX-055 is an oncolytic immunotherapy being developed by ImmVirX Pty Ltd for the treatment of bladder cancer. It is a self-amplifying, non-enveloped, single-positive-stranded RNA virus designed to selectively infect, replicate within, and destroy tumor cells. This process not only causes direct oncolysis but also induces a systemic anti-tumor immune response by altering the tumor microenvironment. IVX-055 is part of ImmVirX's proprietary platform that utilizes receptor-targeted RNA viruses to preferentially target cancer cells while sparing healthy tissue. As of early 2025, the drug is in preclinical development with plans to enter clinical trials.

Targets

EPHA3 (Ephrin Receptor A3)

Beyond the preview

Go deeper on IVX-055.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IVX-055.

Explore the full profile